Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Weight loss through lifestyle changes is recommended for nonalcoholic fatty liver disease (NAFLD). However, its efficacy in patients with type 2 diabetes is unproven. RESEARCH DESIGN AND METHODS: Look AHEAD (Action for Health in Diabetes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12 months. We defined steatosis >5.5% as NAFLD. RESULTS: Participants were 49% women and 68% white. The mean age was 61 years, mean BMI was 35 kg/m2, mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months, participants assigned to ILI (n = 46) lost more weight (−8.5 vs. −0.05%; P < 0.01) than those assigned to DSE and had a greater decline in steatosis (−50.8 vs. −22.8%; P = 0.04) and in A1C (−0.7 vs. −0.2%; P = 0.04). There were no significant 12-month changes in AST or ALT levels. At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at baseline developed NAFLD (P < 0.05). CONCLUSIONS: A 12-month intensive lifestyle intervention in patients with type 2 diabetes reduces steatosis and incident NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, histological improvement of different MASLD components depended on the amount of weight loss: Whereas about 5-7 % of weight loss already lead to a reduction in liver lipid content in 65 % of people with MASLD, MASH resolution (defined as the absence of hepatocellular ballooning) was achieved in 64 % by a 7-10 % decrease in body weight [46][47][48][49].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a 12‐month lifestyle intervention program in patients with type 2 diabetes, hepatic steatosis and incident NAFLD was significantly reduced [28].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Obesity, diabetes, and insulin resistance are the main risk factors for more advanced forms of the disease; up to 70–80% of individuals with NAFLD have insulin resistance or metabolic syndrome (3).”
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying Disease
Caldwell, S. H., Oelsner, D. H., Iezzoni, J. C., Hespenheide, E. E., Battle, E. H., & Driscoll, C. J. (1999) · Hepatology · doi:10.1002/hep.510290347 · Cited by 1,143
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Cited by
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Self-citationHernaez, R., Lazo, M., Bonekamp, S., Kamel, I., Brancati, F. L., Guallar, E., & Clark, J. M. (2011) · Hepatology · doi:10.1002/hep.24452 · Cited by 1,585
Self-citationTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
“Randomized clinical trials have shown promising results by using lifestyle modification (41, 42), vitamin E and pioglitazone (43), and rosiglitazone (44), but there is no US Food and Drug Administration–approved drug for treating NAFLD.”
Self-citationNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“These results have been replicated by other hypocaloric feeding studies (Lazo et al., 2010; Lim et al., 2011).”
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 683
“• 7–10% total weight loss target A 12-month intensive lifestyle intervention with an average 8% weight loss leads to significant reduction of hepatic steatosis [108].”
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674
“Likewise, a low-calorie diet was effective in achieving weight loss of at least 5 % and improvement of NAFLD [242,246,255].”
BackgroundMethodMusso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.128 · Cited by 585
Self-citationThoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523
“05) reductions in overall NAFLD histological activity score (NAS) and steatosis, but reductions in parenchymal inflammation and ballooning injury were not significant, and there was no mean change in fibrosis in the intervention relative to the control group or baseline [37].”
BackgroundInfluentialEASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 521
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 457
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., Cortez-Pinto, H., Grieco, A., Machado, M. V., Miele, L., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.08.004 · Cited by 444
ESPEN practical guideline: clinical nutrition in liver disease
Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383
Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., Zanolin, E., Schena, F., Bonora, E., & Moghetti, P. (2013) · Hepatology · doi:10.1002/hep.26393 · Cited by 350
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1050-7 · Cited by 327
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Sullivan, S., Kirk, E. P., Mittendorfer, B., Patterson, B. W., & Klein, S. (2012) · Hepatology · doi:10.1002/hep.25548 · Cited by 301
Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence
Zelber-Sagi, S. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i29.3377 · Cited by 300
Marchesini, G., Petta, S., & Dalle Grave, R. (2016) · Hepatology · doi:10.1002/hep.28392 · Cited by 292
“Several studies have tested the effectiveness of lifestyle modifications in NAFLD (Table 4)((58-73)); only a few are based on solid behavioral strategies, not simply on intensive counseling for healthy diet and habitual physical activity.”
BackgroundSpengler, E. K., & Loomba, R. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 284
Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
Jegatheesan, P., & De Bandt, J. (2017) · Nutrients · doi:10.3390/nu9030230 · Cited by 280
“In NASH patients, a 3% to 7% weight loss is associated with decreased hepatic steatosis [84]: Exercise prevents fructose-induced hypertriglyceridemia in healthy subjects and promotes a decrease in hepatic TG content [85].”
BackgroundTrevaskis, J. L., Griffin, P. S., Wittmer, C., Neuschwander-Tetri, B. A., Brunt, E. M., Dolman, C. S., Erickson, M. R., Napora, J., Parkes, D. G., & Roth, J. D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00476.2011 · Cited by 277
Tokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01796-x · Cited by 270
“therapies have been reported to improve serum transaminase levels as well as liver fat as measured by US and magnetic resonance imaging (MRI) in NAFLD patients [62, 63].”
BackgroundKASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J.-J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Kim, S. G., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 267
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 268
Evidence-based European recommendations for the dietary management of diabetes
The Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD), Aas, A.-M., Axelsen, M., Churuangsuk, C., Hermansen, K., Kendall, C. W. C., Kahleova, H., Khan, T., Lean, M. E. J., Mann, J. I., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05894-8 · Cited by 262
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z., & Sanyal, A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 262
“The only other RCT of dietary intervention and exercise in NAFLD was conducted in type 2 diabetics and did not have histological endpoints [48].”
BackgroundDiabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K. H., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 233
Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226
“Current treatment of NAFLD is aimed at weight loss through lifestyle interventions involving diet and exercise [17–20].”
BackgroundGastrointestinal complications of diabetes mellitus
Krishnan, B. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i3.51 · Cited by 226
Watanabe, M., Tozzi, R., Risi, R., Tuccinardi, D., Mariani, S., Basciani, S., Spera, G., Lubrano, C., & Gnessi, L. (2020) · Obesity Reviews · doi:10.1111/obr.13024 · Cited by 215
Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease
Perdomo, C. M., Frühbeck, G., & Escalada, J. (2019) · Nutrients · doi:10.3390/nu11030677 · Cited by 211
“Diabetes) [14] is a multicenter clinical trial including 5145 overweight adults with T2D.”
BackgroundOrci, L. A., Gariani, K., Oldani, G., Delaune, V., Morel, P., & Toso, C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.036 · Cited by 209
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 204
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12511 · Cited by 200
Impact of different ectopic fat depots on cardiovascular and metabolic diseases
Ferrara, D., Montecucco, F., Dallegri, F., & Carbone, F. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28821 · Cited by 195
“Indeed, weight reduction alone can decrease hepatic TG content by up to 80% (Lazo et al., 2010).”
BackgroundObesity in South and Southeast Asia—A new consensus on care and management
Tham, K. W., Abdul Ghani, R., Cua, S. C., Deerochanawong, C., Fojas, M., Hocking, S., Lee, J., Nam, T. Q., Pathan, F., Saboo, B., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13520 · Cited by 187
Management of non-alcoholic fatty liver disease
Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 177
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
The Look AHEAD Trial: a review and discussion of its outcomes
Pi-Sunyer, X. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0099-x · Cited by 176
“The ILI group showed improved biomarkers of glucose and lipid control (7,12), improved blood pressure (7,14), less sleep apnea (17, 18), lower liver fat (19), less depression (20,21), less urinary incontinence (22), less severe kidney disease and retinopathy (23), reduced need of diabetes medications (24), maintenance…”
BackgroundDiets and nonalcoholic fatty liver disease: The good and the bad
Asrih, M., & Jornayvaz, F. R. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2013.11.003 · Cited by 175
Patel, N. S., Doycheva, I., Peterson, M. R., Hooker, J., Kisselva, T., Schnabl, B., Seki, E., Sirlin, C. B., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.039 · Cited by 173
Dietary strategies implicated in the prevention and treatment of metabolic syndrome
De la Iglesia, R., Loria-Kohen, V., Zulet, M., Martinez, J., Reglero, G., & Ramirez de Molina, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111877 · Cited by 168
“Weight loss is achieved via fat mobilization from different body compartments as a consequence of the lipolysis process necessary to provide energy substrate [32,33].”
BackgroundBurra, P., Bizzaro, D., Gonta, A., Shalaby, S., Gambato, M., Morelli, M. C., Trapani, S., Floreani, A., Marra, F., Brunetto, M. R., et al. (2021) · Liver International · doi:10.1111/liv.14943 · Cited by 162
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
Lomonaco, R., Sunny, N. E., Bril, F., & Cusi, K. (2013) · Drugs · doi:10.1007/s40265-012-0004-0 · Cited by 158
“[97] (2010) 96 Diet ? exercise (48) 8 ; 51 0.”
Zelber‐Sagi, S., Godos, J., & Salomone, F. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16638830 · Cited by 150
“04), with a clear dose–response relationship between the level of weight loss and reduction of steatosis [Lazo et al. 2010].”
BackgroundTokushige, K., Ikejima, K., Ono, M., Eguchi, Y., Kamada, Y., Itoh, Y., Akuta, N., Yoneda, M., Iwasa, M., Yoneda, M., et al. (2021) · Hepatology Research · doi:10.1111/hepr.13688 · Cited by 162
Smart, N. A., King, N., McFarlane, J. R., Graham, P. L., & Dieberg, G. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-096197 · Cited by 140
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern
Dhamija, E., Paul, S. B., & Kedia, S. (2019) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1456_17 · Cited by 162
Cuthbertson, D. J., Shojaee-Moradie, F., Sprung, V. S., Jones, H., Pugh, C. J. A., Richardson, P., Kemp, G. J., Barrett, M., Jackson, N. C., Thomas, E. L., et al. (2016) · Clinical Science · doi:10.1042/cs20150447 · Cited by 138
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
Lange, N. F., Radu, P., & Dufour, J.-F. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.025 · Cited by 133
Clinical approaches to non-alcoholic fatty liver disease
Schwenger, K. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1712 · Cited by 133
Zeng, X.-F., Varady, K. A., Wang, X.-D., Targher, G., Byrne, C. D., Tayyem, R., Latella, G., Bergheim, I., Valenzuela, R., George, J., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156028 · Cited by 124
Shojaee-Moradie, F., Cuthbertson, D. J., Barrett, M., Jackson, N. C., Herring, R., Thomas, E. L., Bell, J., Kemp, G. J., Wright, J., & Umpleby, A. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2353 · Cited by 116
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice
Malloy, V. L., Perrone, C. E., Mattocks, D. A. L., Ables, G. P., Caliendo, N. S., Orentreich, D. S., & Orentreich∥, N. (2013) · Metabolism · doi:10.1016/j.metabol.2013.06.012 · Cited by 123
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
(2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.4.325 · Cited by 125
“It was also confirmed that a 5% reduction in body weight due to exercise and diet induced a significant decrease in liver fat content,(107) and a few prospective studies using MRS have also reported that weight loss was associated with a decrease in liver fat content.(105,108,109) Moreover, in two randomized, controll…”
BackgroundResultEskridge, W., Cryer, D. R., Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., & Sanyal, A. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196216 · Cited by 111
New horizons. A new paradigm for treating to target with second-generation obesity medications
Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab848 · Cited by 110
Abdelbasset, W. K., Tantawy, S. A., Kamel, D. M., Alqahtani, B. A., Elnegamy, T. E., Soliman, G. S., & Ibrahim, A. A. (2020) · Medicine · doi:10.1097/md.0000000000019471 · Cited by 108
“Lifestyle modifications such as exercise training and dietary control reduce IHTG and improve themetabolic function in patients with nonalcoholic fatty liver disease.([13,14]) Several documents provided that exercise and physical activity training are well-advised as an important protocol in management of NAFLD.”
BackgroundExercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications
Thyfault, J. P., & Rector, R. S. (2020) · Diabetes · doi:10.2337/dbi18-0043 · Cited by 109
Abdelbasset, W. K., Tantawy, S. A., Kamel, D. M., Alqahtani, B. A., & Soliman, G. S. (2019) · Medicine · doi:10.1097/md.0000000000014918 · Cited by 109
Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe?
Chen, J., Deng, X., Liu, Y., Tan, Q., Huang, G., Che, Q., Guo, J., & Su, Z. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.47143 · Cited by 134
“aminotransferase (AST), aspartate aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT)], metabolic parameters (fasting plasma glucose level and insulin sensitivity), and the triglyceride concentration in the liver [via proton nuclear magnetic resonance (NMR) spectroscopy] in 6 to 12 months [100, 101].”
MethodWang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet
Abenavoli, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16831 · Cited by 103
Non-alcoholic fatty liver disease and cardiovascular risk
Brea, Á., & Puzo, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.085 · Cited by 122
“inase levels and the histological parameters [118–122].”
Tokuhara, D. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.700058 · Cited by 112
Current therapeutic strategies in non‐alcoholic fatty liver disease
Dowman, J. K., Armstrong, M. J., Tomlinson, J. W., & Newsome, P. N. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01403.x · Cited by 100
“investigated the effect of a similar ILI programme on hepatic steatosis in a cohort of 96 overweight adults with type 2 diabetes [52].”
BackgroundAvenell, A., Robertson, C., Skea, Z., Jacobsen, E., Boyers, D., Cooper, D., Aceves-Martins, M., Retat, L., Fraser, C., Aveyard, P., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22680 · Cited by 99
Gut Microbiota and Lifestyle Interventions in NAFLD
Houghton, D., Stewart, C. J., Day, C. P., & Trenell, M. I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040447 · Cited by 111
“those expended ay incorporate a nu ber of interventions including exercise/physical activity independent of eight loss [47–49], diet odification [50–52] or diet and exercise/physical activity [30,31,53,54].”
BackgroundJirapinyo, P., Kumar, N., Alsamman, M. A., & Thompson, C. C. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.11.044 · Cited by 102
Farhangi, M. A., Javid, A. Z., & Dehghan, P. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2015.10.009 · Cited by 107
“009 at content, liver fibrosis [25], and improvement in insulin esistance [26].”
BackgroundNonalcoholic fatty liver disease and microvascular complications in type 2 diabetes
Lv, W.-S. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i20.3134 · Cited by 92
Health Benefits of Long-Term Weight-Loss Maintenance
Rueda-Clausen, C. F., Ogunleye, A. A., & Sharma, A. M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034434 · Cited by 91
Wing, R. R., & the Look AHEAD Research Group (2021) · Obesity · doi:10.1002/oby.23158 · Cited by 88
Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
Chakravarthy, M. V., Siddiqui, M. S., Forsgren, M. F., & Sanyal, A. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592373 · Cited by 88
Hydes, T., Ravi, S., Loomba, R. S., & Gray, M. E. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0067 · Cited by 93
“Lazo et al.(21) (2010) Overweight adults (BMI ≥25 kg/m(2)) with T2DM who underwent proton magnetic resonance spectroscopy of the liver (n=96) Ancillary study linked to the “Look AHEAD” RCT.”
BackgroundUtzschneider, K. M., Bayer-Carter, J. L., Arbuckle, M. D., Tidwell, J. M., Richards, T. L., & Craft, S. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512002966 · Cited by 81
“Conversely, weight loss has been shown to decrease liver fat content (22–25) and improve liver histology (23,24) .”
Joshi, S., Shamanna, P., Dharmalingam, M., Vadavi, A., Keshavamurthy, A., Shah, L., & Mechanick, J. I. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.08.016 · Cited by 81
Lim, S. L., Johal, J., Ong, K. W., Han, C. Y., Chan, Y. H., Lee, Y. M., & Loo, W. M. (2020) · JMIR mHealth and uHealth · doi:10.2196/14802 · Cited by 78
The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights
Federico, A., Rosato, V., Masarone, M., Torre, P., Dallio, M., Romeo, M., & Persico, M. (2021) · Nutrients · doi:10.3390/nu13041314 · Cited by 91
Lu, S., Xie, Q., Kuang, M., Hu, C., Li, X., Yang, H., Sheng, G., Xie, G., & Zou, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04047-0 · Cited by 88
“also had similar findings that weight loss will greatly improve liver steatosis [67, 68].”
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
Niederseer, D., Wernly, B., Aigner, E. S., Stickel, F., & Datz, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030467 · Cited by 93
McPherson, S., Armstrong, M. J., Cobbold, J., Corless, L., Anstee, Q. M., Aspinall, R., Barclay, S. T., Brennan, P. N., Cacciottolo, T. M., Goldin, R. D., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00061-9 · Cited by 105
Filozof, C., Goldstein, B. J., Williams, R. N., & Sanyal, A. (2015) · Drugs · doi:10.1007/s40265-015-0437-3 · Cited by 77
“05) [66].”
Dudekula, A., Rachakonda, V., Shaik, B., & Behari, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111808 · Cited by 74
“Multiple trials have demonstrated that weight loss reduces intrahepatic fat content and improves serum aminotransferases [7–11].”
BackgroundInsulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T., Preiss, D., Sattar, N., Fraser, A., & Waugh, N. (2011) · Health Technology Assessment · doi:10.3310/hta15380 · Cited by 74
Lee, B., Lee, Y., Park, C., Rhee, E., Lee, W., Kim, N. H., Choi, K. M., Park, K., Choi, Y., Soo, B., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0010 · Cited by 86
Åberg, F., Luukkonen, P. K., But, A., Salomaa, V., Britton, A., Petersen, K. M., Bojesen, S. E., Balling, M., Nordestgaard, B. G., Puukka, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.021 · Cited by 73
Metadata
- Authors
- Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., & for the Fatty Liver Subgroup of the Look AHEAD Research Group
- Affiliations
- Johns Hopkins University (US)
- Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;
- Duke Medical Center (US)
- Wake Forest University Health Sciences (US)
- Division of Endocrinology, Diabetes and Nutrition, St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York;
- University of Washington (US)
- Corresponding author
- Lazo, Mariana
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-07-27
- Volume
- 33
- Issue
- 10
- Pages
- 2156-2163
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2945152
- OpenAlex
- W2086657936
- Cited by
- 367
- References
- 24
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 17 · 2023: 18 · 2022: 26 · 2021: 27 · 2020: 31 · 2019: 24 · 2018: 15 · 2017: 17 · 2016: 35 · 2015: 23 · 2014: 26 · 2013: 29 · 2012: 22
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Johns Hopkins University (M01-RR-00052)
- National Institutes of Health (RR-00052)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57149, U01DK57149, U01DK057149, P30DK079637, R01DK060427)
- National Center for Research Resources (M01 RR-00052, M01RR000052)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, non-alcoholic fatty liver disease, hepatic steatosis, intensive lifestyle intervention, weight loss, Look AHEAD trial, 1H NMR, diabetes support and education, glycemic control
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Life Style, Male, Middle Aged, Weight Loss, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
